About Onconic Therapeutics
Onconic Therapeutics is a company based in Seoul (South Korea) founded in 2020.. Onconic Therapeutics has raised $19.9 million across 1 funding round from investors including Aju IB Investment, Stonebridge Capital and Premier Partners. The company has 29 employees as of December 31, 2024. Onconic Therapeutics operates in a competitive market with competitors including Ironwood Pharma, Ardelyx, Tonix Pharma, PanTher Therapeutics and RedHill Biopharma, among others.
- Headquarter Seoul, South Korea
- Employees 29 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Onconic Therapeutics, Inc.
-
Annual Revenue
$10.06 M (USD)-29.53as on Dec 31, 2024
-
Net Profit
$-5.49 M (USD)-581as on Dec 31, 2024
-
EBITDA
$-2.95 M (USD)-261.46as on Dec 31, 2024
-
Total Equity Funding
$19.9 M (USD)
in 1 rounds
-
Latest Funding Round
$19.9 M (USD), Series B
Dec 09, 2022
-
Investors
Aju IB Investment
& 8 more
-
Employee Count
29
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Onconic Therapeutics
Onconic Therapeutics is a publicly listed company on the KRX with ticker symbol 476060 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Onconic Therapeutics
Onconic Therapeutics has successfully raised a total of $19.9M through 1 strategic funding round. The most recent funding activity was a Series B round of $19.9 million completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series B — $19.9M
-
First Round
First Round
(09 Dec 2022)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2022 | Amount | Series B - Onconic Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Onconic Therapeutics
Onconic Therapeutics has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Aju IB Investment, Stonebridge Capital and Premier Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage tech and life sciences focused VC & PE firm
|
Founded Year | Domain | Location | |
|
Private equity & venture capital firm
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Onconic Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Onconic Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Onconic Therapeutics Comparisons
Competitors of Onconic Therapeutics
Onconic Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, Ardelyx, Tonix Pharma, PanTher Therapeutics and RedHill Biopharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Next-generation medicines for CNS and immunological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Drug delivery systems for inoperable solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases
|
|
| domain | founded_year | HQ Location |
Therapeutics for gastrointestinal diseases are developed and provided.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Onconic Therapeutics
Frequently Asked Questions about Onconic Therapeutics
When was Onconic Therapeutics founded?
Onconic Therapeutics was founded in 2020 and raised its 1st funding round 2 years after it was founded.
Where is Onconic Therapeutics located?
Onconic Therapeutics is headquartered in Seoul, South Korea.
Who is the current CEO of Onconic Therapeutics?
John Kim is the current CEO of Onconic Therapeutics.
Is Onconic Therapeutics a funded company?
Onconic Therapeutics is a funded company, having raised a total of $19.9M across 1 funding round to date. The company's 1st funding round was a Series B of $19.9M, raised on Dec 09, 2022.
How many employees does Onconic Therapeutics have?
As of Dec 31, 2024, the latest employee count at Onconic Therapeutics is 29.
What is the annual revenue of Onconic Therapeutics?
Annual revenue of Onconic Therapeutics is $10.06M as on Dec 31, 2024.
What does Onconic Therapeutics do?
Onconic Therapeutics was founded in 2020 and is headquartered in Seoul, South Korea. Focus is placed on developing pharmaceutical treatments within the oncology and gastroenterology sectors. The lead candidate, JPI-547, functions as a dual inhibitor targeting PARP and Tankyrase for pancreatic cancer applications. Another program involves JP-1366, a proton pump inhibitor designed for reflux esophagitis management. Operations emphasize drug candidate advancement through research and clinical stages.
Who are the top competitors of Onconic Therapeutics?
Onconic Therapeutics's top competitors include Ironwood Pharma, PanTher Therapeutics and Tonix Pharma.
Is Onconic Therapeutics publicly traded?
Yes, Onconic Therapeutics is publicly traded on KRX under the ticker symbol 476060.
Who are Onconic Therapeutics's investors?
Onconic Therapeutics has 9 investors. Key investors include Aju IB Investment, Stonebridge Capital, Premier Partners, BNH INVESTMENT, and DAOL Ventures.
What is Onconic Therapeutics's ticker symbol?
The ticker symbol of Onconic Therapeutics is 476060 on KRX.